Report Overview

The South Korea Spinal Muscular Atrophy (SMA) Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach xx billion by 2028, exhibiting a CAGR of around 5.2% during the forecast period.

Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disease characterized by muscle atrophy and weakness. The disease generally manifests early in life and is the leading genetic cause of death in infants and toddlers. SMA is caused by defects in the Survival Motor Neuron 1 (SMN1) gene that encodes the SMN protein. The SMN protein is critical to the health and survival of the nerve cells in the spinal cord responsible for muscle contraction (motor neurons). It is one of the most common rare disease. Spinal muscular atrophy affects 1 in 6,000 to 1 in 10,000 people.

The genetics of SMA provides a unique opportunity for therapeutic development. SMN2 also makes SMN protein, but at greatly reduced efficiency, leading to lower-than-normal levels of the protein. SMN2 provides an attractive target for developing SMA therapeutics, and the majority of drug development efforts in the field are focused on increasing SMN protein production from this gene.



Market Drivers

Initiatives undertaken by various public, as well as non-profit, organizations for creating awareness regarding SMA is driving the market growth. Increase in R&D investment by major companies will boost the market growth in the forecast period. Granting of various drug designation to novel drugs is also accelerating the market growth for spinal muscular atrophy treatment.

High cost of treatment for spinal muscular atrophy is hindering the market growth. Lack of experienced professionals and less adoption rate of spinal muscular atrophy treatment options is restraining the market growth.